A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

NCT00273936 Phase 1 COMPLETED

The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.

Details

Lead sponsor	Vertex Pharmaceuticals Incorporated
Phase	Phase 1
Status	COMPLETED
Enrolment	72
Start date	2006-01

Conditions

• Acute Leukemia
• Chronic Leukemia
• Multiple Myeloma
• Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma
• Waldenstrom's Macroglobulinemia

Interventions

• AVN-944 capsules for oral administration

Countries

United States